Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
ConclusionsPopulation models were developed for 5-HMT and MCC in pediatric patients. Weight-based simulations indicated that 4 mg QD for pediatric patients weighing 25–35 kg and 8 mg QD for those weighing> 35 kg provided similar exposures to those in adults following 8 mg QD and a clinically meaningful CFB MCC.Clinical Trial NumbersNCT00857896, NCT01557244
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Clinical Trials | Drugs & Pharmacology | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Pediatrics